Biotech Wrap: Q1 Puts Sector In Critical Condition –

With the public markets inching toward bear territory during most of the first quarter, it is not terribly surprising that private equity disbursements have slowed down as well. That market retardation, however, has appeared more like a downward plunge when it comes to last year’s golden VC sector: biotechnology.

Investments into biotech plays dropped off by 53.6% this quarter, compared to the same quarter last year, according to our